Table 1 The characteristics of patients with ovarian cancer
From: In vitro drug testing using patient-derived ovarian cancer organoids
Original ID | Sample ID | Cancer type | Age | FIGO stage | Neoadjuvant chemotherapy | Debulking status | Adjuvant chemotherapy | Survival status | BRCA geme status | Organoid culture | Organoid expansion |
|---|---|---|---|---|---|---|---|---|---|---|---|
OvCa-19 | HGSC-1 | High grade serous | 54 | IIIC | Not received | Suboptimal | Paclitaxel and carboplatin x 6 cycles, followed by lipodox x12 cycles, then second debulking then paclitaxel and carboplatin x6 cycles | Alive | Wild type | Success | No |
OvCa-21 | EM-1 | Endometrioid | 40 | IC1 | Not received | Optimal | Paclitaxel and carboplatin x 9 cycles | Alive | Unexamined | Failed | - |
OvCa-26 | MC-1 | Mucinous | 37 | IVB | Not received | Optimal | Paclitaxel and carboplatin x 6 cycles, followed by lipodox x 3 cycles, then gemcitabine and carboplatin x3 cycles | Expired | Unexamined | Success | Yes |
OvCa-28 | MC-2 | Mucinous | 66 | IIIA | Not received | Optimal | Not received due to acute stroke | Expired | Unexamined | Success | Yes |
OvCa-29 | HGSC-2 | High grade serous | 61 | IVB | Not received | Suboptimal | Paclitaxel and carboplatin x 4 cycles, followed by interval debulking, then paclitaxel and carboplatin x 6 cycles, then lipodox, carboplatin and bevacizumab x6 cycles | Alive | Wild type | Success | Yes |
OvCa-32 | HGSC-3 | High grade serous | 62 | IVB | Not received | Suboptimal | Paclitaxel and carboplatin x 4 cycles, followed by interval debulking, then paclitaxel and carboplatin x 6 cycles, then lipodox, carboplatin and bevacizumab x6 cycles | Alive | Wild type | Failed | - |
OvCa-33 | HGSC-4 | High grade serous | 41 | IIIC | Not received | Suboptimal | Paclitaxel and carboplatin x 6 cycles, then lipodox x 6 cycles | Alive | Mutation | Success | Yes |
OvCa-34 | MC-3 | Mucinous | 43 | IC1 | Not received | Optimal | Paclitaxel and cisplatin x4 cycles, then lipodox and bevacizumab x 5 cycles, then gemcitabine and bevacizumab x 2 cycles, then topotecan x 8 cycles | Expired | Unexamined | Failed | - |
OvCa-37 | CCSC-1 | Carcinosarcoma | 61 | IIIC | Not received | Optimal | Paclitaxel, carboplatin and bevacizumab x 9 cycles, followed by second debulking, then bevacizumab, paclitaxel and carboplatin x 6 cycles, then lipodox x 3 cycles, then gemcitabine x2 cycles | Expired | Wild type | Success | Yes |
OvCa-38 | CCC-1 | Clear cell | 32 | IC1 | Not received | Optimal | Paclitaxel and carboplatin x 4 cycles | Alive | Unexamined | Success | Yes |
OvCa-40 | CCC-2 | Clear cell | 49 | IIIC | Bevacizumab, paclitaxel and cisplatin x 3 cycle then paclitaxel and carboplatin x 2 cycle | Suboptimal | Gemcitabine and carboplatin x1 cycle | Expired | Unexamined | Success | Yes |
OvCa-41 | CCC-3 | Clear cell | 50 | IIIB | Not received | Optimal | Rejected | Expired | Unexamined | Success | Yes |
OvCa-42 | MC-4 | Mucinous | 47 | IC1 | Not received | Optimal | Not received | Alive | Unexamined | Success | Yes |
OvCa-43 | HGSC-5 | High grade serous | 55 | IIIC | Paclitaxel and carboplatin x 4 cycle | Optimal | Paclitaxel and carboplatin x 2 cycles, followed by lipodox x 3 cycles, then gemcitabine x3 cycle | Expired | Wild type | Success | Yes |
OvCa-44 | EM-2 | Endometrioid | 58 | IIB | Not received | Suboptimal | Paclitaxel and cisplatin x 6 cycles, then lipodox x 3 cycles, then gemcitabine and cisplatin x2 cycles, followed by secondary optimal debulking, then gemcitabine and cisplatin x2 cycles | Alive | Not received | Success | Yes |
OvCa-45 | HGSC-6 | High grade serous | 70 | IIIC | Not received | Optimal | Paclitaxel and carboplatin x 6 cycles, then lipodox and carboplatin x4 cycles | Alive | Unexamined | Success | No |
OvCa-46 | MC-5 | Mucinous | 44 | IC1 | Not received | Optimal | Not received | Alive | Unexamined | Success | Yes |
OvCa-49 | HGSC-7 | High grade serous | 55 | IIIC | Paclitaxel and cisplatin x 4 cycle | Optimal | Paclitaxel and carboplatin x 2 cycles, followed by lipodox x 3 cycles, then gemcitabine x3 cycles | Expired | Wild type | Success | Yes |
OvCa-50 | CCC-4 | Clear cell | 45 | IIIC | Not received | Optimal | Paclitaxel and carboplatin x 1 cycle, then second debulking surgery, followed by lipodox and bevacizumab x 1 cycle, then gemcitabine, carboplatin and bevacizumab x 8 cycles. | Alive | Unexamined | Success | Yes |
OvCa-51 | CCSC-2 | Carcinosarcoma | 51 | IIIA2 | Not received | Optimal | Paclitaxel and cisplatin x 1 cycle, then gemcitabine and paclitaxel x 3 cycles | Expired | Unexamined | Failed | - |
OvCa-54 | CCC-6 | Clear cell | 51 | IIB | Not received | Optimal | Paclitaxel and cisplatin x 6 cycles | Alive | Unexamined | Success | Yes |